RDPAC's Lobbying Efforts To Regulate China's Medical Representatives Likely To Pay Off This Year
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - As China rolls out its 12th five-year economic development plan, the R&D-based Pharmaceutical Association Committee (RDPAC) - an industry association representing multinational biopharma companies in China - is suggesting a friendlier regulatory environment for foreign companies
You may also be interested in...
Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference
SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation
Japanese Pharma To Beef Up Transparency Policies In 2011 To Counter Public Concern - APEC Regulatory Conference
SEOUL - Japanese pharma agreed to rollout updated in-house transparency guidelines in 2011 to strengthen compliance and improve the industry's public reputation
Are Chinese Price Cut Fears Overstated? Volume Likely To Drive Pharma Industry Growth, Analysts Say
SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach